Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors

Author(s): Lili Cao, Weiguo Song, Erik De Clercq, Peng Zhan, Xinyong Liu

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 17 , 2014

Become EABM
Become Reviewer


Reverse transcription of human immunodeficiency virus type 1 (HIV-1) is a crucial step in the life cycle initiated by the viral-coded reverse transcriptase (RT), functioning as RNA- and DNA-dependent DNA polymerase (RDDP and DDDP) and the ribonuclease H (RNase H). The RNase H functions to degrade the RNA strand of the RNA:DNA heteroduplex, which makes it an attractive target for rational anti-HIV-1 drug design and development. Although development of drugs targeting the DNA polymerase have been highly successful, the discovery of drugable inhibitors of HIV RNase H is still in its infancy and none of RNase H inhibitors has reached the clinical development stage currently. This review describes the recent progress in the HIV-1 RNase H inhibitors, focusing on their chemical feature, mechanism and the structure-activity relationship (SAR).

Keywords: AIDS, drug design, HIV-1, RNase H inhibitors, RT, SAR.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [1956 - 1967]
Pages: 12
DOI: 10.2174/0929867321666140120121158
Price: $65

Article Metrics

PDF: 62